セッション

Targeting hematopoietic cell kinase with imatinib has therapeutic potential for NK/T cell neoplasms

[演者] Luis Espinoza:1
[著者] Ken Ishiyama:1, Kenichi Harada:1, Takeshi Yoroidaka:1, Ly Trung:1, Shinji Nakao:1
1:Hematol., Kanazawa University, Japan

Early progression of disease in patients with newly diagnosed localized ENKL treated with RT-DeVIC

[演者] Ritsuro Suzuki (鈴木 律朗):1
[著者] Motoko Yamaguchi (山口 素子):2, Masahiko Oguchi (小口 正彦):3, Naoko Asano (浅野 直子):5, Kana Miyazaki (宮崎 香奈):2, Kyoko Ueda (上田 響子):4, Nobuko Kubota (久保田 靖子):6, Takeshi Maeda (前田 猛):7, Yukio Kobayashi (小林 幸夫):8, Jun Amaki (天木 惇):9, Tohru Murayama (村山 徹):10, Bungo Saito (齋藤 文護):11, Emiko Shimoda (下田 絵美子):12, Noriko Fukuhara (福原 規子):13, Norifumi Tsukamoto (塚本 憲史):14, Kazuyuki Shimada (島田 和之):15, Naokuni Uike (鵜池 直邦):16, Takahiko Utsumi (内海 貴彦):17, Naoyuki Katayama (片山 直之):2
1:Oncol. Hematol., Shimane Univ., Izumo, Japan, 2:Hematol. Oncol., Mie Univ., Tsu, Japan, 3:Radiation Oncol., Cancer Institute Hospital, Tokyo, Japan, 4:Hematol. Oncol., Cancer Institute Hospital, Tokyo, Japan, 5:Mol. Diagn., Nagano Prefectural Suzaka Hospital, Suzaka, Japan, 6:Hematol., Saitama Cancer Center, Ina, Japan, 7:Hematol. Oncol., Kurashiki Central Hospital, Kurashiki, Japan, 8:Hematol., National Cancer Center Hospital, Tokyo, Japan, 9:Hematol. Oncol., Tokai University, Isehara, Japan, 10:Hematol., Hyogo Cancer Center, Akashi, Japan, 11:Hematol., Showa University, Tokyo, Japan, 12:Radiation Oncol., Nara Medical University, Kashihara, Japan, 13:Hematol. Rheumatol., Tohoku University, Sendai, Japan, 14:Cancer Center, Gunma University, Maebashi, Japan, 15:Hematol., Nagoya University, Nagoya, Japan, 16:Hematol., Kyushu Cancer Center, Fukuoka, Japan, 17:Hematol. Oncol., Shiga Medical Center, Moriyama, Japan

Phase II multi-center trial of dose-adjusted EPOCH therapy for untreated peripheral T-cell lymphoma

[演者] Isao Yoshida (吉田 功):1
[著者] Yoshinobu Maeda (前田 嘉信):2, Hisakazu Nishimori (西森 久和):2, Yasushi Hiramatsu (平松 靖史):3, Masatoshi Uno (海野 正俊):4, Yasufumi Masaki (正木 康史):5, Kazutaka Sunami (角南 一貴):6, Taro Masunari (増成 太郎):7, Yuichiro Nawa (名和 由一郎):8, Hiromichi Yamane (山根 弘路):9, Hiroshi Gomyo (五明 広志):10, Tsutomu Takahashi (高橋 勉):11, Tomofumi Yano (矢野 朋文):12, Keitaro Matsuo (松尾 恵太郎):13, Koichi Ohshima (大島 孝一):14, Shigeo Nakamura (中村 栄男):15, Tadashi Yoshino (吉野 正):16, Mitsune Tanimoto (谷本 光音):2
1:Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, 2:Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan, 3:Hematology/Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan, 4:Department of Internal Medicine, Kaneda Hospital, Maniwa, Japan, 5:Department of Hematology and Immunology, Kanazawa Medical University, Kahoku-gun, Japan, 6:Department of Hematology, NHO Okayama Medical Center, Okayama, Japan, 7:Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan, 8:Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan, 9:Department of General Internal Medicine-IV, Kawasaki Medical School, Okayama, Japan, 10:Department of Hematology, Hyogo Cancer Center, Akashi, Japan, 11:Department of Oncology/Hematology, Shimane University Hospital, Izumo, Japan, 12:Department of Hematology, Okayama Rosai Hospital, Okayama, Japan, 13:Molecular and Clinical Epidemiology, Aichi Cancer Center, Nagoya, Japan, 14:Department of Pathology, School of Medicine, Kurume University, Kurume, Japan, 15:Department of Pathology, Nagoya University Hospital, Nagoya, Japan, 16:Department of Pathology, Okayama University, Okayama, Japan

Protective effects of KIR-2DS1, KIR-2DS5 and KIR-2DL5 on EBV-related iatrogenic lymphoma (IA-LPD)

[演者] Mai Anh Nguyen Thi:1,2
[著者] Viet Hoang Nguyen:1, Mahmoud I. Elbadry:1,3, Takeshi Yoroidaka:1, Tatsuya Imi:1, Go Aoki:1, Ken Ishiyama:1, Shinji Nakao:1
1:Hematology Department, Kanazawa University, Ishikawa, Japan, 2:Pediatric Department, Faculty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam, 3:Hematology Division, Department of Internal Medicine, Faculty of Medicine, Sohag University Hospital, Sohag, Egypt

TCL-001: A phase I/II Japanese study of romidepsin in relapsed/refractory peripheral T-cell lymphoma

[演者] Masafumi Taniwaki:1
[著者] Dai Maruyama:2, Kensei Tobinai:2, Michinori Ogura:3,4, Kiyohiko Hatake:5, Toshiki Uchida:4, Kiyoshi Ando:6, Kunihiro Tsukasaki:7, Takashi Ishida:8, Naoki Kobayashi:9, Kenichi Ishizawa:10,11, Yoichi Tatsumi:12, Koji Kato:13, Toru Kiguchi:14, Takayuki Ikezoe:15,16, Eric Laille:17, Tokihiro Ro:18, Hiromi Tamakoshi:18, Sanae Sakurai:18, Tomoko Ohtsu:18
1:Department of Hematology and Center for Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine, Kyoto, Japan, 2:Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 3:Department of Hematology, Tokai Central Hospital, Gifu, Japan, 4:Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Aichi, Japan, 5:Department of Hematology and Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, 6:Department of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan, 7:Department of Hematology, National Cancer Center Hospital East, Chiba, Japan, 8:Department of Hematology and Oncology, Nagoya City University Hospital, Aichi, Japan, 9:Department of Hematology, Sapporo Hokuyu Hospital, Hokkaido, Japan, 10:Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan (present), 11:Department of Hematology and Rheumatology, Tohoku University Hospital, Miyagi, Japan (previous), 12:Department of Hematology & Rheumatology, Kinki University Hospital, Faculty of Medicine, Osaka, Japan, 13:Department of Hematology and Oncology, Kyushu University Hospital, Fukuoka, Japan, 14:Department of Hematology, Chugoku Central Hospital, Hiroshima, Japan, 15:Department of Hematology & Respiratory Medicine, Kochi Medical School Hospital, Kochi, Japan (previous), 16:Department of Hematology, Fukushima Medical University School of Medicine, Japan (present), 17:Celgene Corporation, Overland Park, KS, USA, 18:Celgene K.K., Tokyo, Japan

詳細検索